Division of Cardiology, Washington University School of Medicine, 660 S. Euclid, Campus Box 8086, St. Louis, MO, 63110, USA.
Missouri Baptist Medical Center, St. Louis, MO, USA.
Curr Cardiol Rep. 2018 May 19;20(7):50. doi: 10.1007/s11886-018-0995-6.
Recent studies have demonstrated a higher risk of incident diabetes associated with statin use, causing concern among patients and clinicians. In this review, we will assess the evidence and proposed mechanisms behind statin therapy and its association with incident diabetes. We will then review the current recommendations for statin use in light of this association and suggest next steps for clinicians managing these patients and researchers exploring this phenomenon.
The annual risk of developing new-onset diabetes with statin treatment is approximately 0.1%. In comparison, the absolute risk reduction of major coronary events with statin use is approximately 0.42% annually. Statins are associated with the development of incident diabetes, particularly among those with predisposing risk factors for diabetes. However, the benefit of statin use among these patients in preventing major coronary events strongly favors statin use despite its risk of incident diabetes.
最近的研究表明,他汀类药物的使用与新发糖尿病的风险增加有关,这引起了患者和临床医生的关注。在这篇综述中,我们将评估他汀类药物治疗及其与新发糖尿病之间关联的证据和提出的机制。然后,我们将根据这一关联审查他汀类药物使用的当前建议,并为管理这些患者的临床医生和探索这一现象的研究人员提出下一步建议。
使用他汀类药物治疗新发糖尿病的年风险约为 0.1%。相比之下,使用他汀类药物治疗的主要冠状动脉事件的绝对风险降低约为每年 0.42%。他汀类药物与新发糖尿病的发生有关,尤其是在有糖尿病易感因素的患者中。然而,尽管他汀类药物有新发糖尿病的风险,但在这些患者中使用他汀类药物预防主要冠状动脉事件的益处大大超过了其风险。